About us

Cell and gene therapy will allow us to replenish and heal our bodies.
As we continue to harness the power of our biology, treatments will become cures.

Locate Bio is a privately owned cell and gene therapy company developing life changing therapies using breakthrough technologies that overcome current industry limitations. Our in-house focus areas are liver, hematology, CNS and bone but our technologies can be applied to many more disease areas

Our History

Based in Nottingham, UK, the company was established in 2001 (as RegenTec Limited) as a spin-out from the University of Nottingham spin-out based on the research of Professor Kevin Shakesheff, a world-leading key opinion leader in regenerative medicine

The company developed a substantial intellectual property portfolio, and successfully transitioned from contract research into a product development company in 2014.

Since 2014, the company has both optimised its TAOS® technology and established its product development capabilities, as indicated by the award of ISO 13485:2016 certification. Its lead product, which is partnered with Heraeus Medical, a leading orthopaedics company. 

We have also in-licensed another cutting-edge technology in IntraStem, a promising new transfection technology for gene therapy that provides key benefits over current viral and non-viral delivery systems. Our current focus is to expand our pipeline into new therapy areas with exciting new gene therapy programmes.

The company continues to benefit from the advances and inventions of Professor Shakesheff’s multidisciplinary research team via a fruitful intellectual property pipeline.


"Our mission is ambitious but our strategy is simple:
to utilise our breakthrough technologies to develop products ourselves in our areas of therapeutic focus, while providing partner companies access to our technologies for use in other therapy areas, so we can improve the lives of patients worldwide." 
Nick Staples

Looking to the future

We are expanding the application of our technologies to therapy areas beyond our current bone repair pipeline, so we can develop new products for liver, hematology and CNS diseases.

Our initial product development strategy has utilised TAOS for regenerative medicine applications in bone repair (orthopedics) to provide important validation of the technology in cell therapy and regenerative medicine in general.

TAOS has potential cell therapy applications in a range of tissues throughout the body and we have previously generated compelling in vivo results in areas such as stroke. We have not however initiated our own development programmes in these areas to date but these represent areas for potential future collaboration.

IntraStem provides exciting new product opportunities, as it has a broad range of potential applications including gene therapy and ex vivo cell therapy modification and offers major advantages over current approaches.

Locate is currently evaluating a number of new cell and gene therapy product opportunities across ex vivo, local in vivo and systemic in vivo applications both for in-house development and for potential third party collaborations.